Skip to main content
. Author manuscript; available in PMC: 2015 Sep 9.
Published in final edited form as: Mol Pharm. 2015 Aug 7;12(9):3237–3249. doi: 10.1021/acs.molpharmaceut.5b00183

Table 4.

Crosslinking numbers for peptide-peptide adducts (X11*) values (± SD, n=3) for each lyophilized formulation.

Group X11* (± SD)
Control Raffinose Gdn HCl
1 0.7 ± 0.6 1.7 ± 0.6 4.7 ± 0.6
2 0.4 ± 0.4 1.2 ± 0.4 1.6 ± 0.7
3 0.4 ± 0.2 0.9 ± 0.0 1.9 ± 0.3
4 1.0 ± 0.1 0.9 ± 0.1 2.6 ± 0.4
5 0.3 ± 0.6 0.8 ± 0.1 1.4 ± 0.1
6 1.8 ± 0.3 2.1 ± 0.3 3.4 ± 0.2
7 0.9 ± 0.2 0.4 ± 0.2 2.2 ± 0.3
8 1.2 ± 0.1 1.6 ± 0.2 2.6 ± 0.3
Total (ΣX11*) 6.8 ± 1.7 9.7 ± 1.5 20.5 ± 1.5